GI Innovation Inc. Logo

GI Innovation Inc.

Develops fusion protein biologics for oncology, allergic, and metabolic diseases.

358570 | KO

Overview

Corporate Details

ISIN(s):
KR7358570000
LEI:
Country:
South Korea
Address:
서울특별시 송파구 송파대로 167, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GI Innovation Inc. is a biopharmaceutical company engaged in the research and development of next-generation immunotherapies. The company utilizes its proprietary GI-SMART™ platform to create innovative fusion protein-based biologics. Its development pipeline targets diseases with high unmet medical needs, focusing on therapeutic areas such as immuno-oncology (GI-101, GI-10N), allergic and fibrotic diseases (GI-301, GI-30N), and metabolic diseases (GI-20N). Operating under a "Science, Strategy, Speed" philosophy, GI Innovation advances its drug candidates through well-structured translational research and strategic collaborations with global pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (건강한 성인 및 암 생존자를 대상으로 한 GI102 요법의 노화 관련 생…
Korean 8.2 KB
2025-09-05 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (GI101 단일 요법 또는 펨브롤리주맙 또는 렌바티닙 병용 요법의 안…
Korean 13.0 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-09-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 957.2 KB
2025-08-29 00:00
Share Issue/Capital Change
전환주식의전환청구권행사 (전환우선주)
Korean 15.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-05 00:00
Share Issue/Capital Change
주요사항보고서(전환사채매수선택권행사자지정)
Korean 23.8 KB
2025-07-10 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-06-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 604.9 KB
2025-06-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-06-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB

Automate Your Workflow. Get a real-time feed of all GI Innovation Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GI Innovation Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GI Innovation Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF
Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE

Talk to a Data Expert

Have a question? We'll get back to you promptly.